Market Overview

Moderna's Coronavirus Vaccine Secures Swiss Regulatory Approval

Moderna's Coronavirus Vaccine Secures Swiss Regulatory Approval

Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate mRNA-1273 gained another regulatory approval Tuesday. 

Separately, the company also announced a high-profile executive appointment.

Sixth Approval Secured: Cambridge, Massachusetts-based Moderna said Tuesday that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized its vaccine in Switzerland.

The authorization was issued according to the "ordinary approvals" procedure, and was based on a rolling submission of data and the totality of scientific evidence shared by the company, Moderna said.

Related Link: The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off

The Swiss government has secured 7.5 million doses of mRNA-1273. Moderna expects to begin delivery of the first doses next week.

The company's vaccine has already been conditionally approved in the U.S., Canada, Israel, U.K. and European Union. 

Moderna Strengthens Executive Team: The company announced the appointment of José M. Vega as its chief safety officer effective Jan. 11. He will report to Moderna's chief medical officer Tal Zaks.

Vega was most recently with Merck & Co., Inc. (NYSE: MRK), where he was heading the Global Clinical Safety and Pharmacovigilance organization, and was also functioning as chief safety officer for Merck Research Labs.

In premarket trading Tuesday, Moderna shares were edging up 0.2% to $117.50.

Related Link: The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue


Related Articles (MRNA)

View Comments and Join the Discussion!

Posted-In: Coronavirus Covid-19 vaccineBiotech News Health Care General Best of Benzinga